References
- Lücking U. Sulfoximines: a neglected opportunity in medicinal chemistry. Angew Chem Int Ed Engl. 2013;52(36):9399–9408.
- Srivastava S, Srivastava S. Biological activity of Quinazoline: a review. Int J Pharma Sci Res. 2015;6(9):1206–1213.
- National Cancer Institute at the National Institutes of Health. NCI Drug Dictionary. U.S. Department of Health and Human Services, 2015; [cited 2016 Feb 15]. Available from: http://www.cancer.gov/publications/dictionaries/cancer-drug
- Adis International Ltd, part of Springer Science Business Media. Springer International Publishing AG; 2015; [Last accessed 2016 Feb 23]. Available from: http://adisinsight.springer.com/drugs/800009452
- Asif M. Chemical characteristics, synthetic methods, and biological potential of quinazoline and quinazolinone derivatives. Int J Med Chem. 2014;10:1–27.
- Boehringer Ingelhelm International Gmbh. Sulfoximine substituted quinazolines for pharmaceutical compositions. US 20140135309 A1; 2014.
- Boehringer Ingelhelm International Gmbh. Sulfoximine substituted quinazolines for pharmaceutical compositions. WO2015082324 A1; 2015.
- Hou J, Lam F, Proud C, et al. Targeting Mnks for cancer therapy. Oncotarget. 2012;3(2):118–131.
- Joshi S, Platanias LC. Mnk kinase pathway: cellular functions and biological outcomes. World J Biol Chem. 2014;5(3):321–333.
- De-Velogen AG Novel use of pyrazolopyrimidines. WO 2006066937 A2; 2006.
- De-Velogen AG Thienopyrimidines for pharmaceutical compositions. WO 2006136402 A1; 2006.
- Pharmacopeia, Inc. 8-Heteroarylpurine Mnk2 inhibitors for treating metabolic disorders. WO 2007104053 A2; 2007.
- Stead RL, Proud CG. Rapamycin enhances eIF4E phosphorylation by activating MAP kinase-interacting kinase 2a (Mnk2a). FEBS Lett. 2013;587(16):2623–2628.
- Marzec M, Liu X, Wysocka M, et al. Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells. PLoS One. 2011;6(9):16.
- Konicek BW, Stephens JR, McNulty AM, et al. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases. Cancer Res. 2011;71(5):1849–1857.
- Tschopp C, Knauf U, Brauchle M, et al. Phosphorylation of eIF-4E on Ser 209 in response to mitogenic and inflammatory stimuli is faithfully detected by specific antibodies. Mol Cell Biol Res Commun. 2000;3(4):205–211.
- Winssinger N, Barluenga S. Chemistry and biology of resorcylic acid lactones. Chem Commun. 2007;1:22–36.
- Teo T, Yang Y, Yu M, et al. An integrated approach for discovery of highly potent and selective Mnk inhibitors: screening, synthesis and SAR analysis. Eur J Med Chem. 2015;103:539–550.
- Kannan S, Poulsen A, Yang HY, et al. Probing the binding mechanism of Mnk inhibitors by docking and molecular dynamics simulations. Biochemistry. 2015;54(1):32–46.
- Brazeau J-F, Rosse G. Pyrrolopyrimidine analogues as MKNK Inhibitors. ACS Med Chem Lett. 2015;6(1):9–10.
- Bayer Pharma AG Substituted pyrrolopyrimidines. WO 2013174743 Al; 2013.
- Okamura H, Bolm C. Rhodium-catalyzed imination of sulfoxides and sulfides: efficient preparation of N-unsubstituted sulfoximines and sulfilimines. Org Lett. 2004;6(8):1305–1307.
- Mancheno OG, Bistri O, Bolm C. Iodinane and metal-free synthesis of N-cyano sulfilimines: novel and easy access of NH-sulfoximines. Org Lett. 2007;9(19):3809–3811.
- Mkhalid IAI, Barnard JH, Marder TB, et al. C-H activation for the construction of C-B bonds. Chem Rev. 2010;110(2):890–931.
- Moessner C, Bolm C. Cu(OAc)2-catalyzed N-arylations of sulfoximines with aryl boronic acids. Org Lett. 2005;7(13):2667–2669.
- Boehringer Ingelhelm International Gmbh. Sulfoximine substituted pyrrolotriazines for pharmaceutical compositions. WO 2015091156 Al; 2015.